Strategies to Combat Human Epidermal Growth Factor Receptor 2 (HER2) Resistance in HER2-Positive Breast Cancer

The discovery of human epidermal growth factor receptor 2 (HER2) and its role in breast cancer led to the development of the first targeted antibody treatment for HER2-positive breast cancer. This treatment breakthrough led to remarkable improvements in both early and late survival. Unfortunately, n...

Full description

Saved in:
Bibliographic Details
Published inCritical reviews in oncogenesis Vol. 25; no. 3; p. 209
Main Authors Rajarajan, Noeline, Mariotti, Veronica, Basu, Amrita, Kodumudi, Krithika, Han, Heather, Czerniecki, Brian, Hoover, Susan
Format Journal Article
LanguageEnglish
Published United States 2020
Online AccessGet more information

Cover

More Information
Summary:The discovery of human epidermal growth factor receptor 2 (HER2) and its role in breast cancer led to the development of the first targeted antibody treatment for HER2-positive breast cancer. This treatment breakthrough led to remarkable improvements in both early and late survival. Unfortunately, not all patients with HER2 breast cancer responded positively; some have innate resistance to treatment and others develop resistance over time. In this review, we discuss some research that is currently underway to understand HER2 resistance and strategies in overcoming it.
ISSN:0893-9675
2162-6448
DOI:10.1615/CritRevOncog.2020036417